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Identity 
Other names: TSP1; platelet glycoprotein G 
HGNC (Hugo): THBS1 
Location: 15q15 
Local order: Telomeric to FLJ39531, centromeric to 




The THBS1 gene is 16,393 bases in size and is 
composed of 22 exons. Exons 2-21 encode the 5729 b 
mRNA. 
Transcription 
Egr-1 and Sp1 sites function in the constitutive 
transcription of THBS1 stimulated by serum. 
Transcription is regulated by c-Jun/AP-1 in cooperation 
with the repressor Yin Yang-1 (YY-1) and by p53. 
USF2 mediates glucose-induced TSP1 transcription. 
Id1 represses transcription. The ATF-1 transcription 
factor also down-regulates transcription of TSP1 
through an ATF/cAMP-responsive element-binding 
protein binding site. In contrast, Myc increases 
turnover of thrombospondin-1 mRNA. Transcription of 





Intron-exon organization of the THBS1 gene. 
 
Domain organization and localization of selected ligand binding sites in TSP1. TSP1 is a homotrimer linked via disulfide bonds. 











The TSP1 precursor contains 1170 amino acids; 
129,412 Da. The mature secreted protein comprises 
residues 19-1170 and assembles into a disulfide linked 
homotrimer. Secreted TSP1 is a glycoprotein with a 
molecular mass of 150-180 kDa that contains 
approximately 12 Asn-linked mono-, bi- tri-, and 
tetraantennary complex oligosaccharides and variable 
numbers of C-mannosylated Trp residues in the type 1 
repeats. 
Expression 
TSP1 is expressed in many tissues during embryonic 
development but has limited expression in the healthy 
adult. TSP1 is the most abundant protein in alpha 
granules of platelets, but normal plasma levels are very 
low (typically 100-200 ng/ml). Expression in other cell 
types is induced by wounding, during tissue 
remodeling, in atherosclerotic lesions, rheumatoid 
synovium, glomerulonephritis, and in stroma of many 
tumors. Conversely, most but not all malignant cells in 
tumors exhibit loss of TSP1 expression during 
malignant progression. This loss is due to diminished 
positive regulation of the THBS1 gene by suppressor 
genes such as p53 and NM23 and increased negative 
regulation by oncogenes including Ras and Myc. TSP1 
expression is induced by TGF-beta, vitamin A, 
progesterone, and retinoids and suppressed by nickel, 
Id1, and hepatocyte growth factor. TSP1 expression in 
the epidermis of skin is suppressed following exposure 
to UV irradiation. 
Localisation 
TSP1 is secreted and present transiently in extracellular 
matrix but is rapidly internalized for degradation by 
fibroblasts and endothelial cells. TSP1 is abundant in 
megakaryocytes and platelets and is constitutively 
expressed at the dermal-epidermal boundary in skin 
and in subendothelial matrix of some blood vessels. 
Function 
TSP1 binds to extracellular matrix ligands including 
fibrinogen, fibronectin, some collagens, latent and 
active transforming growth factor-beta-1, TSG6, 
heparin, plasmin, cathepsin G, neutrophil elastase, 
some MMPs, tissue factor pathway inhibitor, and 
heparan sulfate proteoglycans. TSP1 binds to cell 
surface receptors including CD36, CD47, some 
syndecans, LDL receptor-related protein-1 (via 
calreticulin) and the integrins alpha-V/beta-3, alpha-
3/beta-1, alpha-4/beta-1, and alpha-6/beta-1. TSP1 is a 
slow tight inhibitor of plasmin, cathepsin G, and 
neutrophil elastase. TSP1 directly binds and activates 
latent TGF-beta-1. TSP1 in a context-dependent and 
cell-specific manner stimulates or inhibits cell  
adhesion, proliferation, motility, and survival. TSP1 is 
a potent inhibitor of angiogenesis, but N-terminal 
proteolytic and recombinant parts of TSP1 have clear 
pro-angiogenic activities mediated by beta-1 integrins. 
In the immune system, TSP1 is a potent inhibitor of T 
cell and dendritic cell activation and mediates clearance 
of apoptotic cells by phagocytes. In the CNS, TSP1 
secreted by astrocytes promotes synaptogenesis. 
Based on studies of TSP1 null mice, platelet TSP1 is 
not essential for platelet aggregation, but TSP1 null 
mice have impaired wound repair, increased retinal 
angiogenesis, and are hyper-responsive to several 
inflammatory stimuli. 
Homology 
TSP1 is a member of the thrombospondin family that 
also contains thrombospondin-2, -3, -4, and cartilage 
oligomeric matrix protein (COMP). The central type 1 
repeats are also known as thrombospondin-repeats and 




a2210g (Asn700Ser) premature familial myocardial 
infarction; alters Ca-binding to TSP1. 
g1678a (Thr523Ser) genetic risk factor of cerebral 




Associated with local invasive behavior, tumor 
neovascularization, and metastasis. 
Prognosis 
Decreased TSP1 expression has been correlated with 
malignant progression and decreased survival in several 
cancers. To date, the strongest data is for colorectal 
carcinomas. Five independent studies involving more 
than 400 patients have shown significant association of 
reduced TSP1 expression with increased invasion, 
microvascular densities, and poor prognosis. More 
limited studies have shown associations of decreased 
TSP1 with poor prognosis in squamous non-small cell 
lung carcinoma, pancreatic adenocarcinoma, invasive 
cervical carcinoma, and oral squamous cell carcinomas. 
TSP1 is generally not a useful prognostic factor in 
breast or prostate cancers, although one study of 58 
breast DCIS showed loss of stromal TSP1 in DCIS 
with more aggressive histological features. Recent 
evidence indicates that the failure of TSP1 to protect in 
most breast cancers is due to an escape mechanism 
involving increased VEGF expression. Finally, TSP1 
was positively correlated with invasion in 
hepatocellular and ovarian carcinomas. 










Mutation of THBS1 has not been reported in cancers, 
but loss of THBS1 expression due to hypermethylation, 
transcriptional regulation by oncogenes or tumor 
suppressor genes, or altered mRNA stability has been 
reported in many cancers. Transgenic mouse models 
support the tumor suppressor activity of THBS1. Mice 
lacking TSP1 develop tumors earlier in a p53 null 
background. Conversely, transgenic mice 
overexpressing TSP1 in skin or mammary tissue are 
resistant to chemical or oncogene-driven 
carcinogenesis. 
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